<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862745</url>
  </required_header>
  <id_info>
    <org_study_id>GA0221IX</org_study_id>
    <nct_id>NCT00862745</nct_id>
  </id_info>
  <brief_title>Bringing Simple Urge Incontinence Diagnosis &amp; Treatment to Providers (BRIDGES)</brief_title>
  <acronym>BRIDGES</acronym>
  <official_title>A Multi-center, Randomized, Placebo-controlled Clinical Trial Comparing Fesoterodine to Placebo in Women Diagnosed With Urge Urinary Incontinence by the 3 Incontinence Questions (3IQ). Followed by a Multi-center Open Label Clinical Cohort Study of Long-term Effects of Treatment With Fesoterodine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a
      three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of
      fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the
      US. All participants who complete the 12-week randomized trial will be offered open-label
      fesoterodine for an additional 9 months.

      The hypothesis of the randomized controlled trial is that among women diagnosed with urge
      incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean
      number of urge incontinence episodes per day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">645</enrollment>
  <condition>Urge Urinary Incontinence</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine</intervention_name>
    <description>Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory females ≥ 18 years old

          -  Urge Urinary Incontinence (subject-reported) for ≥ 3 months prior to Screening (Visit
             1)

          -  On the 3IQ: Response b to Question 3: During the last 3 months, did you leak urine
             most often: b. When you had the urge or the feeling that you needed to empty your
             bladder, but could not get to the toilet fast enough?

          -  On a 3-day bladder diary, documentation of an average of 1 UUI episode per 24 hours (3
             UUI episodes in 3 days)

          -  Capability of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risk and benefits

          -  Ability to perform all procedures and tests required by the protocol

          -  Willingness to remain on stable medication regime for duration of the randomized
             controlled trial. Participants will be asked to not add new medications during the
             randomized controlled trial, such as diuretics and other medications which may affect
             their voiding pattern.

        Exclusion Criteria:

          -  Any condition that would contraindicate their usage of fesoterodine including:
             hypersensitivity to the active drug (fesoterodine fumarate) and its ingredients or any
             of the excipients, history of urinary retention, gastric retention, uncontrolled
             narrow angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C),
             severe ulcerative colitis, toxic megacolon, fistula or a hole in your bladder or
             rectum, birth defect leading to urine leakage, and urine leakage starting in
             childhood.

          -  Clinically significant hepatic or renal disease.

          -  Neurologic conditions such as stroke, multiple sclerosis, spinal cord injury, or
             Parkinson's disease.

          -  Symptomatic pelvic organ prolapse defined as participant report of feeling or seeing a
             bulge outside the vagina within the past 3 months.

          -  History of lower urinary tract/pelvic surgery (e.g. surgery for incontinence in the
             past 5 years, surgery in the past 6 months for prolapse or hysterectomy),
             intra-vesical therapy (botox), and/or bulk injections within the past 6 months.

          -  A known history of interstitial cystitis or a significant pain component associated
             with OAB symptoms, uninvestigated hematuria, urogenital cancer, interstitial or
             external radiation to the pelvis or external genitalia.

          -  Urinary tract infection (UTI) as shown by the results of the urinalysis at screening
             or recurrent urinary tract infection (RUTIs) defined as treatment for UTI &gt;3 times in
             the last year.

          -  Use of any electrostimulation, bladder training, or pelvic floor exercises (with
             certified incontinence practitioners) within 4 weeks of Screening.

          -  Received study medication in any previous fesoterodine clinical trial.

          -  Prior failure for either efficacy or tolerability of ≥ 2 OAB medications in the last
             year. (failure: inadequate symptom control after two medications for a minimum of one
             month each)

          -  Has been treated within 2 weeks prior to Screening and/or is currently being treated
             with: - Any drug treatment for overactive bladder, including antimuscarinic OAB
             medications.

          -  Any drugs with significant anticholinergic and antispasmodic effects (see exception
             for tricyclic antidepressants below)

          -  Has started treatment with tricyclic antidepressants or estrogens within 4 weeks prior
             to Screening and/or is not on a stable dose.

          -  Intermittent or unstable use of diuretics. Treatment with diuretics initiated within 2
             weeks prior to baseline is not permitted.

          -  Treatment with potent CYP3A4 inhibitors, such as clarithromycin, ketoconazole, and
             itraconazole within 2 weeks prior to Screening.

          -  Administration of medications capable of inducing hepatic enzyme metabolism or
             transport (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St.
             John's Wort) in the past 30 days.

          -  Previously received any investigational drug within 30 days prior to trial entry.

          -  Alcohol and/or any other drug abuse in the opinion of the investigator.

          -  Participants who are pregnant, nursing, or with a positive urine pregnancy test or who
             are intending to become pregnant within 3 months after the completion of the trial.

          -  Participants that have been pregnant (&gt; 20 weeks gestation) in the previous 6 months.

          -  Participants of childbearing potential who are heterosexually active but unwilling or
             unable to use an adequate form of contraception to prevent pregnancy during the study.
             Reliable contraceptive methods may include intrauterine devices (IUD), contraceptive
             pills of combination type, hormonal implants, injectable contraceptives or latex
             condoms with a spermicide.

          -  Participants who have any medical (including known history of major hematological,
             renal, cardiovascular, or hepatic abnormalities) or psychological condition or social
             circumstances that would impair their ability to participate reliably in the trial, or
             those who may increase the risk to themselves or others by participating.

          -  Participants who, in the opinion of the investigator, are not likely to complete the
             trial for whatever reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanette S. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants' Hospital, Division of Urogynecology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia-Women's Midlife Health Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>September 14, 2011</results_first_submitted>
  <results_first_submitted_qc>October 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2011</results_first_posted>
  <last_update_submitted>October 19, 2011</last_update_submitted>
  <last_update_submitted_qc>October 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jeanette Brown</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the general community surrounding 13 clinical sites across the United States between January 2009 and December 2009.</recruitment_details>
      <pre_assignment_details>Participants screened over 4 week period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fesoterodine</title>
          <description>fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Control Trial</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="323"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268">19 participants elected not to enter the open-label portion of the study after completing the RCT.</participants>
                <participants group_id="P2" count="274">10 participants elected not to enter the open-label portion of the study after completing the RCT.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fesoterodine</title>
          <description>fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="322"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="645"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="14.7"/>
                    <measurement group_id="B2" value="55.9" spread="14.2"/>
                    <measurement group_id="B3" value="56.0" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="322"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="322"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The population analyzed included all participants receiving at least 1 dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine</title>
            <description>fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.</title>
          <population>The population analyzed included all participants receiving at least 1 dose of study intervention.</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.5"/>
                    <measurement group_id="O2" value="-1.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: fesoterodine treatment is not associated with greater reduction in urgency incontinence frequency compared to placebo in women diagnosed using the 3IQ</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons, threshold for significance is P &lt; .05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean difference=Drug A minus Drug B</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through Week 12 (Randomized Control Trial portion of the study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fesoterodine</title>
          <description>fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Room Visit for Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="322"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Hosptialized for Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for Diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="322"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="322"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Hospitalization for Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="322"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Hospitalization for Pulmonary embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="322"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="322"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold/flu</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="322"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Runny/stuffy nose, sinus congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="322"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eyes/mouth/throat</sub_title>
                <counts group_id="E1" events="137" subjects_affected="107" subjects_at_risk="322"/>
                <counts group_id="E2" events="54" subjects_affected="38" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="322"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeanette Brown</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-9751</phone>
      <email>brownj@obgyn.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

